GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OTCPK:ORXOY) » Definitions » EV-to-FCF

ORXOY (Orexo AB) EV-to-FCF : -19.02 (As of Dec. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Orexo AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orexo AB's Enterprise Value is $84.79 Mil. Orexo AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.46 Mil. Therefore, Orexo AB's EV-to-FCF for today is -19.02.

The historical rank and industry rank for Orexo AB's EV-to-FCF or its related term are showing as below:

ORXOY' s EV-to-FCF Range Over the Past 10 Years
Min: -75.87   Med: -3.76   Max: 26.99
Current: -21.9

During the past 13 years, the highest EV-to-FCF of Orexo AB was 26.99. The lowest was -75.87. And the median was -3.76.

ORXOY's EV-to-FCF is ranked worse than
100% of 552 companies
in the Drug Manufacturers industry
Industry Median: 25.86 vs ORXOY: -21.90

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), Orexo AB's stock price is $1.185. Orexo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.295. Therefore, Orexo AB's PE Ratio (TTM) for today is At Loss.


Orexo AB EV-to-FCF Historical Data

The historical data trend for Orexo AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB EV-to-FCF Chart

Orexo AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.70 -8.68 -4.37 -4.63 -7.32

Orexo AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.85 -7.32 -11.37 -17.07 -20.97

Competitive Comparison of Orexo AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Orexo AB's EV-to-FCF falls into.



Orexo AB EV-to-FCF Calculation

Orexo AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=84.794/-4.458
=-19.02

Orexo AB's current Enterprise Value is $84.79 Mil.
Orexo AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orexo AB  (OTCPK:ORXOY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Orexo AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.185/-0.295
=At Loss

Orexo AB's share price for today is $1.185.
Orexo AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.295.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Orexo AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Orexo AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB Business Description

Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.